Full-Time
Confirmed live in the last 24 hours
Develops therapies using targeted protein degradation
Senior, Expert
Belmont, MA, USA
Hybrid work model with a minimum of 3 days/week in the office.
You match the following Kymera Therapeutics's candidate preferences
Employers are more likely to interview you if you match these preferences:
Kymera Therapeutics develops treatments by targeting and breaking down specific proteins that contribute to diseases, particularly cancer and immune disorders. Their main technology, the Pegasus Platform, enables them to identify these harmful proteins and create drug candidates aimed at effectively treating various conditions. Unlike many competitors, Kymera focuses on targeted protein degradation, which can lead to more precise therapies. The company's goal is to create next-generation medicines that address unmet medical needs, supported by partnerships with organizations like Sanofi to enhance their research and development efforts.
Company Size
201-500
Company Stage
IPO
Total Funding
$191.6M
Headquarters
Cambridge, Massachusetts
Founded
2016
Help us improve and share your feedback! Did you find this helpful?
Hybrid Work Options
WATERTOWN, Mass., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced the pricing of its underwritten public offering of $225 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. Kymera is selling 2,002,313 shares of common stock
Kymera Therapeutics aims to raise $225M: The public offering will be...
Kymera Therapeutics aims to raise $225M: The public offering will be used to fund Kymera's pipeline, and some funds could be used for small acquisitions or in-licensing deals.
Neosphere Biotechnologies and Kymera Therapeutics partner to advance molecular glue target discovery.
Kymera unveiled its first-in-class oral TYK2 degrader, KT-294, at its Immunology R&D Day in January 2024.
Hsbc Holdings PLC makes new investment in Kymera Therapeutics, Inc. (NASDAQ:KYMR).
WATERTOWN, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), will report fourth quarter and full year 2023 financial results on February 22, 2024, and will host a conference call at 8:30 a.m. ET.To access the February 22 conference call via phone, please dial +1 (833) 630-2127 (US) or +1 (412) 317-1846 (International) and ask to join the Kymera Therapeutics call. A live webcast of the Company’s conference call will be available under “News and Events” in the Investors section of the Company’s website at www.kymeratx.com. A replay of the webcast will be archived and available following the event.About Kymera Therapeutics
Kymera Therapeutics announces pricing of $275 million public offering.
WATERTOWN, Mass., Jan. 05, 2024 -- Kymera Therapeutics, Inc. , a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation ,...
WATERTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein